NDAINHALATIONSOLUTION
Approved
Apr 2001
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
14
Data completeness
3/8 — Basic
ACCUNEB (albuterol sulfate) by Teva is clinical pharmacology the prime action of beta-adrenergic drugs is to stimulate adenyl cyclase, the enzyme which catalyzes the formation of cyclic-3',5'-adenosine monophosphate (cyclic amp) from adenosine triphosphate (atp). First approved in 2001.
Drug data last refreshed 13h ago · AI intelligence enriched 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ACCUNEB is an inhaled albuterol sulfate solution administered via nebulizer for acute bronchospasm relief in patients with reversible airway obstruction. It works by stimulating beta-2 adrenergic receptors to relax bronchial smooth muscle and increase airflow. The drug demonstrates rapid onset (within 5 minutes) and peak effect around 1 hour with sustained benefit for approximately 2 hours.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), suggesting defensive positioning and focus on differentiation or market retention strategies.
Mechanism of Action
CLINICAL PHARMACOLOGY The prime action of beta-adrenergic drugs is to stimulate adenyl cyclase, the enzyme which catalyzes the formation of cyclic-3',5'-adenosine monophosphate (cyclic AMP) from adenosine triphosphate (ATP). The cyclic AMP thus formed mediates the cellular responses. In vitro…
Worked on ACCUNEB at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.